Isolated laminin-421

Abstract

The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin 2 chain, expression vectors and host cells thereof.

Claims

1. An isolated recombinant laminin-421 produced by a method comprising: providing host cells that express recombinant laminin-421, wherein the recombinant laminin-421 comprises: a first chain comprising a polypeptide with 100% identity to a polypeptide sequence of SEQ ID NO: 1, a second chain comprising a polypeptide with % identity to a polypeptide sequence of SEQ ID NO: 2, and a third chain comprising a polypeptide with 100% identity to a polypeptide sequence of SEQ ID NO: 3, wherein the first, second, and third chains assemble to form a recombinant trimeric laminin-421 structure; growing the host cells in a cell culture medium under conditions to stimulate expression of the recombinant laminin-421 chains; passing the cell culture medium through a column, wherein the column contains a compound that binds to the recombinant laminin-421; washing the column to remove unbound materials; and eluting the bound recombinant laminin-421 from the column.

2. A pharmaceutical composition, comprising: a) the isolated recombinant laminin-421 of claim 1; and b) a pharmaceutically acceptable carrier.

3. An isolated recombinant laminin-421, comprising: a first chain comprising a polypeptide with 100% identity to a polypeptide sequence of SEQ ID NO: 1; a second chain comprising a polypeptide with 100% identity to a polypeptide sequence of SEQ ID NO: 2; and a third chain comprising a polypeptide with 100% identity to a polypeptide sequence of SEQ ID NO: 3; wherein the first, second, and third chains assemble to form a recombinant trimeric laminin-421 structure.

4. A pharmaceutical composition comprising: a) the isolated recombinant laminin-421 of claim 3; and b) a pharmaceutically acceptable carrier.

Description

DETAILED DESCRIPTION

(1) A more complete understanding of the compositions and methods disclosed herein can be obtained by reference to the following description. The specific details of the description are not intended to define or limit the scope of the exemplary embodiments.

(2) Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular structure of the embodiments described herein, and are not intended to define or limit the scope of the disclosure.

(3) All references, patents and patent applications discussed herein are hereby incorporated by reference in their entirety.

(4) Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), Guide to Protein Purification in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2.sup.nd Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.).

(5) An used herein, an isolated nucleic acid sequence refers to a nucleic acid sequence that is free of gene sequences which naturally flank the nucleic acid in the genomic DNA of the organism from which the nucleic acid is derived (i.e., genetic sequences that are located adjacent to the gene for the isolated nucleic molecule in the genomic DNA of the organism from which the nucleic acid is derived). An isolated laminin 2 chain nucleic acid sequence according to the present disclosure may, however, be linked to other nucleotide sequences that do not normally flank the recited sequence, such as a heterologous promoter sequence, or other vector sequences. It is not necessary for the isolated nucleic acid sequence to be free of other cellular material to be considered isolated, as a nucleic acid sequence according to the disclosure may be part of an expression vector that is used to transfect host cells (see below).

(6) The present disclosure provides recombinant expression vectors comprising a full length laminin 2 chain nucleic acid sequence (SEQ ID NO: 4) of the human laminin 2 chain. In some embodiments, the expression vectors comprise a nucleic acid encoded by SEQ ID NO: 4, operatively linked to a heterologous promoter (i.e. is not the naturally occurring promoter for the given 2 laminin chain). A promoter and a laminin 2 chain nucleic acid sequence are operatively linked when the promoter is capable of driving expression of the laminin 2 chain DNA into RNA.

(7) As used herein, the term vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a plasmid, which refers to a circular double stranded DNA into which additional DNA segments may be cloned. Another type of vector is a viral vector, wherein additional DNA segments may be cloned into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors), are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as recombinant expression vectors or simply expression vectors. In the present disclosure, the expression of the laminin polypeptide sequence is directed by the promoter sequences of the disclosure, by operatively linking the promoter sequences of the disclosure to the gene to be expressed. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, plasmid and vector may be used interchangeably, as the plasmid is the most commonly used form of vector. However, the disclosure is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

(8) The vector may also contain additional sequences, such as a polylinker for subcloning of additional nucleic acid sequences, or a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the methods of the disclosure, and any such sequence may be employed, including but not limited to the SV40 and bovine growth hormone poly-A sites. Also contemplated as an element of the vector is a termination sequence, which can serve to enhance message levels and to minimize read through from the construct into other sequences. Additionally, expression vectors typically have selectable markers, often in the form of antibiotic resistance genes, that permit selection of cells that carry these vectors.

(9) In further embodiments, the present disclosure provides host cells transfected with the laminin 2 chain-expressing recombinant expression vectors disclosed herein. As used herein, the term host cell is intended to refer to a cell into which a nucleic acid of the present disclosure, such as a recombinant expression vector, has been introduced. Such cells may be prokaryotic, which can be used, for example, to rapidly produce a large amount of the expression vectors of the disclosure, or may be eukaryotic, for functional studies.

(10) The terms host cell and recombinant host cell are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

(11) The host cells can be transiently or stably transfected with one or more of the expression vectors of the disclosure. Such transfection of expression vectors into prokaryotic and eukaryotic cells can be accomplished via any technique known in the art, including but not limited to standard bacterial transformations, calcium phosphate co-precipitation, electroporation, or liposome mediated-, DEAE dextran mediated-, polycationic mediated-, or viral mediated transfection. (See, for example, Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press; Culture of Animal Cells: A Manual of Basic Technique, 2.sup.nd Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.).

(12) In another aspect, the present disclosure provides an isolated full length human laminin 2 chain polypeptide consisting of the amino acid sequence of SEQ ID NO: 2.

(13) As used herein, an isolated polypeptide refers to a polypeptide that is substantially free of other proteins, including other laminin chains, and gel agents, such as polyacrylamide and agarose. In preferred embodiments, the isolated laminin polypeptide is free of detectable contaminating laminin chains. Thus, the protein can either be isolated from natural sources, or recombinant protein can be isolated from the transfected host cells disclosed above.

(14) In another aspect, the present disclosure provides isolated laminin-421. As used herein laminin-421 encompasses both recombinant laminin-421 and heterotrimeric laminin-421 from naturally occurring sources. In preferred embodiments, the laminin-421 comprises recombinant laminin-421 (or r-laminin-421).

(15) As used herein, the term r-laminin-421 refers to recombinant heterotrimeric laminin-421, expressed by a host cell that has been transfected with one or more expression vectors comprising at least one nucleic acid sequence encoding a laminin-421 chain selected from the 4, 2 and 1 chains, or processed/secreted forms thereof. Such r-laminin-421 can thus comprise 4, 2, and 1 sequences from a single organism, or from different organisms. Various laminin-421 chain DNA sequences are known in the art, and the use of each to prepare the r-laminin-421 of the disclosure is contemplated. (See, for example, Pouliot, N. et al., Experimental Cell Research 261(2):360-71, (2000); Kikkawa, Y. et al., Journal of Cell Science 113 (Pt 5):869-76, (2000); Church, H J. et al., Biochemical Journal 332 (Pt 2):491-8, (1998); Sorokin, L M. et al., Developmental Biology 189(2):285-300, (1997); Miner, J H. et al., Journal of Biological Chemistry 270(48):28523-6, (1995); Sorokin, L. et al., European Journal of Biochemistry 223(2):603-10, (1994); all references being incorporated by reference herein in their entirety). In preferred embodiments, the r-laminin-421 comprises recombinant human 4, 2, and 1 polypeptide chains.

(16) The disclosure encompasses those laminin molecules wherein only one or two chains that make up the recombinant heterotrimeric laminin-421 are encoded by endogenous laminin-421 chains. In preferred embodiments, each of the 4, 2, and 1 polypeptide chains are expressed recombinantly.

(17) Laminin-421 is a secreted protein, which is capable of being directed to the endoplasmic reticulum (ER), secretory vesicles, and the extracellular space as a result of a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a mature protein. Such processing event can be variable, and thus may yield different versions of the final mature protein. The isolated laminin-421 of the present disclosure includes heterotrimers comprising both the full length and any such processed laminin-421 polypeptide chains.

(18) As used herein, a laminin-421 polypeptide chain refers to a polypeptide chain according to one or more of the following:

(19) (a) a polypeptide chain that comprises a polypeptide structure selected from the group consisting of: R1-R2-R3, R1-R2-R3(e), R3, R3(e), R1-R3, R1-R3(e), R2-R3, and R2-R3(e), wherein R1 is an amino terminal methionine; R2 is a signal sequence that is capable of directing secretion of the polypeptide, wherein the signal sequence may be the natural signal sequence for the particular laminin chain, that of another secreted protein, or an artificial sequence; R3 is a secreted laminin chain selected from the group consisting of a 4 chain, a 2 chain, and a 1 chain; and R3(e) is a secreted 4, 2, or 1 laminin chain that further comprises an epitope tag (such as those described below), which can be placed at any position within the laminin chain amino acid sequence; or

(20) (b) a polypeptide chain that is encoded by a polynucleotide that hybridizes under high or low stringency conditions to the coding regions, or portions thereof, of one or more of the recombinant laminin-421 chain DNA sequences disclosed herein (SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6), or complementary sequences thereof; or

(21) (c) a polypeptide chain that has at least 70% identity to one or more of the disclosed laminin-421 polypeptide chain amino acid sequences (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3), preferably at least 80% identity, and most preferably at least about 90% identity.

(22) Stringency of hybridization is used herein to refer to washing conditions under which nucleic acid hybrids are stable. The disclosure also includes nucleic acids that hybridize under high stringency conditions (as defined herein) to all or a portion of the coding sequences of the laminin chain polynucleotides disclosed herein, or their complements. The hybridizing portion of the hybridizing nucleic acids is typically at least 50 nucleotides in length. As known to those of ordinary skill in the art, the stability of hybrids is reflected in the melting temperature (T.sub.M) of the hybrids. T.sub.M decreases approximately 1-1.5 C. with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. As used herein, high stringency refers to an overnight incubation at 42 C. in a solution comprising 50% formamide, 5SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1SSC at about 65 C.

(23) Also contemplated are laminin-421-encoding nucleic acid sequences that hybridize to the polynucleotides of the present disclosure at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 C. in a solution comprising 6SSPE (20SSPE=3M NaCl; 0.2M NaH.sub.2PO.sub.4; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 g/ml salmon sperm blocking DNA; followed by washes at 50 C. with 1SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5SSC).

(24) Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

(25) As used herein, percent identity of two amino acids or of two nucleic acids is determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264.2268, 1990), modified as in Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches are performed with the NBLAST program, score 100, wordlength=12, to determine nucleotide sequences identity to the nucleic acid molecules of the disclosure. BLAST protein searches are performed with the XBLAST program, score=50, wordlength=3, to determine an amino acid sequence identity to a polypeptide of the disclosure. To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in Altschul et al. (Nucleic Acids. Res. 25:3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used.

(26) Further embodiments of the present disclosure include polynucleotides encoding laminin-421 chain polypeptides having at least 70% identity, preferably at least 80% identity, and most preferably at least 90% identity to one or more of the polypeptide sequences contained in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

(27) As used herein, 4 polynucleotide refers to polynucleotides encoding an laminin 4 chain. Such polynucleotides can be characterized by one or more of the following: (a) polynucleotides that encode polypeptides which share at least 70% identity, preferably 80% identity, and most preferably at least 90% identity with a sequence selected of SEQ ID NO: 5; (b) the 4 polynucleotides hybridize under low or high stringency conditions to the coding sequence of SEQ ID NO: 5 or complementary sequences thereof; or (c) the 4 polynucleotides encode a laminin 4 chain polypeptide with a general structure selected from the group consisting of R1-R2-R3, R1-R2-R3(e), R3, R3(e), R1-R3, R1-R3(e), R2-R3, and R2-R3(e), wherein R1 and R2 are as described above, and R3 and R3(e) are as described above but comprise secreted 4 chain polypeptides.

(28) As used herein, 2 polynucleotides refers to polynucleotides encoding a 2 laminin chain of the same name. Such polynucleotides can be characterized by one or more of the following: (a) polynucleotides that encode polypeptides which share at least 70% identity, preferably at least 80%, and most preferably at least 90% identity with the sequence of SEQ ID NO: 4; (b) the 2 polynucleotides hybridize under low or high stringency conditions to the coding sequences of SEQ ID NO: 4, or complementary sequences thereof; or (c) the 2 polynucleotides encode a polypeptide with a general structure selected from R1-R2-R3, R1-R2-R3(e), R3, R3(e), R1-R3, R1-R3(e), R2-R3, and R2-R3(e), wherein R1 and R2 are as described above, and R3 and R3(e) are as described above but comprise secreted 2 chain polypeptides.

(29) As used herein, 1 polynucleotides refers to polynucleotides encoding a 1 laminin chain of the same name. Such polynucleotides can be characterized by one or more of the following: (a) polynucleotides that encode polypeptides which share at least 70% identity, preferably at least 80%, and most preferably at least 90% identity with the sequence of SEQ ID NO: 6; (b) the 1 polynucleotides hybridize under low or high stringency conditions to the coding sequence of SEQ ID NO: 6 or complementary sequences thereof; or (c) the 1 polynucleotides encode a polypeptide with a general structure selected from R1-R2-R3, R1-R2-R3(e), R3, R3(e), R1-R3, R1-R3(e), R2-R3, and R2-R3(e), wherein R1 and R2 are as described above, and R3 and R3(e) are as described above but comprise secreted 1 chain polypeptides.

(30) As used herein, the term epitope tag refers to a polypeptide sequence that is expressed as part of a chimeric protein, where the epitope tag serves as a recognition site for binding of antibodies generated against the epitope tag, or for binding of other molecules that can be used for affinity purification of sequences containing the tag.

(31) In preferred embodiments, cDNAs encoding the laminin 4, 2 and 1 chains, or fragments thereof, are subcloned into an expression vector. Alternatively, laminin 4, 2 and/or 1 gene sequences, including one or more introns, can be used for subcloning into an expression vector.

(32) In other aspects, the present disclosure provides laminin-421 expressing-cells that have been transfected with an expression vector containing promoter sequences that are operatively linked to nucleic acid sequences encoding at least one polypeptide sequence comprising a sequence selected from the group consisting of the 4, 2 and 1 chains of laminin-421, wherein the transfected cells secrete heterotrimeric laminin-421 containing the recombinant laminin chain. In preferred embodiments, the cells are systematically transfected with recombinant expression vectors containing promoter sequences that are operatively linked to nucleic acid sequences encoding polypeptide sequences comprising the 4, 2 and 1 chains of laminin-421, which are even more preferably all human chains. After the multiple transfections, the cells express recombinant laminin-421 chains, which form the heterotrimeric r-laminin-421.

(33) Transfection of the expression vectors into eukaryotic cells can be accomplished via any technique known in the art, including but not limited to calcium phosphate co-precipitation, electroporation, or liposome mediated-, DEAE dextran mediated-, polycationic mediated-, or viral mediated transfection. Transfection of bacterial cells can be done by standard methods.

(34) In preferred embodiments, the cells are stably transfected. Methods for stable transfection and selection of appropriate transfected cells are known in the art. In other preferred embodiments, a CMV promoter driven expression vector is used in a human kidney embryonic 293 cell line.

(35) Any cell capable of expressing and secreting the r-laminin-421 can be used. Preferably, eukaryotic cells are used, and most preferably mammalian cells are used, including but not limited to kidney and epithelial cell lines. The promoter sequence used to drive expression of the individual chains or r-laminin-421 may be constitutive (driven by any of a variety of promoters, including but not limited to, CMV, SV40, RSV, actin, EF) or inducible (driven by any of a number of inducible promoters including, but not limited to, tetracycline, ecdysone, steroid-responsive). Carbohydrate and disulfide post-translational modifications are believed to be required for laminin-421 protein folding and function. This makes the use of eukaryotic cells preferable for producing functional r-laminin-421, although other systems are useful for obtaining, for example, antigens for antibody production. In most preferred embodiments, the mammalian cells do not express the laminin 2 chain endogenously. In other preferred embodiments, the cells do not express all of the laminin-421 chains endogenously.

(36) The protein may comprise additional sequences useful for promoting purification of the protein, such as epitope tags and transport signals. Examples of such epitope tags include, but are not limited to FLAG (SIGMA CHEMICAL, St. Louis, Mo.), myc (9E10) (INVITROGEN, Carlsbad, Calif.), 6-His (INVITROGEN; NOVAGEN, Madison, Wis.), and HA (Boehringer Manheim Biochemicals). Examples of such transport signals include, but are not limited to, export signals, secretory signals, nuclear localization signals, and plasma membrane localization signals.

(37) In some embodiments, at least one of the laminin chain polypeptide sequences, or fragments thereof, is operatively linked to a nucleic acid sequence encoding an epitope tag, so that at least one of the chains is expressed as a fusion protein with an expressed epitope tag. The epitope tag may be expressed as the amino terminus, the carboxy terminus, or internal to any of the polypeptide chains comprising r-laminin-421, so long as the resulting r-laminin-421 remains functional.

(38) In other embodiments, one of the r-laminin-421 chains is expressed as a fusion protein with a first epitope tag, and at least one other r-laminin chain is expressed as a fusion protein with a second epitope tag. This permits multiple rounds of purification to be carried out. Alternatively, the same epitope tag can be used to create fusion proteins with more than one of the r-laminin chains.

(39) In further embodiments, the epitope tag can be engineered to be cleavable from the r-laminin-421 chain(s). Alternatively, no epitope tag is fused to any of the r-laminin-421 chains, and the r-laminin-421 is isolated by standard techniques, including but not limited to affinity chromatography using laminin-421 specific antibodies or other laminin-421 binding molecules.

(40) Media from cells transfected with a single laminin chain are initially analyzed on Western blots using laminin chain-specific antibodies. The expression of single laminin chains following transfection is generally intracellular. Clones showing reactivity against individual transfected chain(s) are verified by any appropriate method, such as PCR, reverse transcription-PCR, or nucleic acid hybridization, to confirm incorporation of the transfected gene. Preferably, analysis of genomic DNA preparations from such clones is done by PCR using laminin chain-specific primer pairs. Media from transfected clones producing all three chains are further analyzed for r-laminin-421 secretion and/or activity, by any appropriate method, including Western blot analysis and cell binding assays.

(41) In preferred embodiments, purification of r-laminin-421 is accomplished by passing media from the transfected cells through an antibody affinity column. In some embodiments, antibodies against a peptide epitope expressed on at least one of the recombinant chains are attached to an affinity column, and bind the r-laminin-421 that has been secreted into the media. The r-laminin-421 is removed from the column by passing excess peptide over the column. Eluted fractions are analyzed by any appropriate method, including gel electrophoresis and Western blot analysis. In further embodiments, the peptide epitope can be cleaved after purification. In other embodiments, two or three separate r-laminin chains are expressed as fusion proteins, each with a different epitope tag, permitting two or three rounds of purification and a doubly or triply isolated r-laminin-421. The epitope tag can be engineered so as to be cleavable from the r-laminin-421 chain(s) after purification. Alternatively, no epitope tag is fused to any of the r-laminin-421 chains, and the r-laminin-421 is isolated by standard techniques, including but not limited to affinity chromatography using laminin-421 specific antibodies or other laminin-421 binding molecules.

(42) The laminin-421 polypeptide chains of the present disclosure also include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more amino acid residues having substituent groups, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

(43) For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

(44) In particular embodiments, the isolated laminin-421 comprises three chains. The first chain comprises a polypeptide with at least 80% identity to a polypeptide sequence of SEQ ID NO: 1 (i.e. the 4 laminin chain). The second chain comprises a polypeptide with at least 70% identity to a polypeptide sequence of SEQ ID NO: 2 (i.e. the 2 laminin chain). The third chain comprises a polypeptide with at least 70% identity to a polypeptide sequence of SEQ ID NO: 3 (i.e. the 1 laminin chain). These first, second, and third chains are assembled into recombinant laminin-421.

(45) In more specific embodiments, the polypeptide of the first chain has at least 80% identity to the polypeptide sequence of SEQ ID NO: 1, the polypeptide of the second chain has at least 80% identity to the polypeptide sequence of SEQ ID NO: 2, and the polypeptide of the third chain has at least 80% identity to the polypeptide sequence of SEQ ID NO: 3.

(46) In more specific embodiments, the polypeptide of the first chain has at least 90% identity to the polypeptide sequence of SEQ ID NO: 1, the polypeptide of the second chain has at least 90% identity to the polypeptide sequence of SEQ ID NO: 2, and the polypeptide of the third chain has at least 90% identity to the polypeptide sequence of SEQ ID NO: 3.

(47) In particular embodiments, the first chain comprises the polypeptide sequence of SEQ ID NO: 1, the second chain comprises the polypeptide sequence of SEQ ID NO: 2, and the third chain comprises the polypeptide sequence of SEQ ID NO: 3.

(48) In particular embodiments, the first chain is the polypeptide sequence of SEQ ID NO: 1, the second chain is the polypeptide sequence of SEQ ID NO: 2, and the third chain is the polypeptide sequence of SEQ ID NO: 3.

(49) The present disclosure further provides pharmaceutical compositions comprising isolated laminin-421 and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition comprises isolated r-laminin-421. According to these aspects of the disclosure, other agents can be included in the pharmaceutical compositions, depending on the condition being treated. The pharmaceutical composition may further comprise one or more other compounds, including but not limited to any of the collagens, other laminin types, fibronectin, vitronectin, cadherins, integrins, -dystroglycan, entactin/nidogen, -dystroglycan, glycoproteins, proteoglycans, heparan sulfate proteoglycan, glycosaminoglycans, epidermal growth factor, vascular endothelial growth factor, fibroblast growth factor, or nerve growth factors, and peptide fragments thereof.

(50) Pharmaceutical preparations comprising isolated laminin-421 can be prepared in any suitable form, and generally comprise the isolated laminin-421 in combination a pharmaceutically acceptable carrier. The carriers can be injectable carriers, topical carriers, transdermal carriers, and the like. The preparation may advantageously be in a form for topical administration, such as an ointment, gel, cream, spray, dispersion, suspension or paste. The preparations may further advantageously include preservatives, antibacterials, antifungals, antioxidants, osmotic agents, and similar materials in composition and quantity as is conventional. Suitable solutions for use in accordance with the disclosure are sterile, are not harmful for the proposed application, and may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. For assistance in formulating the compositions of the present disclosure, one may refer to Remington's Pharmaceutical Sciences, 15th Ed., Mack Publishing Co., Easton, Pa. (1975).

(51) In further aspects, the present disclosure comprises medical devices with improved biocompatibility, wherein the devices are coated with isolated laminin-421 or pharmaceutical compositions thereof, alone or in combination with other proteins or agents that serve to increase the biocompatibility of the device surface. The coated device stimulates cell attachment (such as endothelial cell attachment), and provides for diminished inflammation and/or infection at the site of entry of the appliance.

(52) Such medical devices can be of any material used for implantation into the body, and preferably are made of or coated with a biocompatible metal that may be either stainless steel or titanium. Alternatively, the device is made of or coated with a ceramic material, or a polymer including but not limited to polyester, polyglycolic acid or a polygalactose-polyglycolic acid copolymer.

(53) If the device is made of a natural or synthetic biodegradable material in the form of a mesh, sheet or fabric, isolated laminin-421 or pharmaceutical compositions thereof may be applied directly to the surface thereof. Appropriate cells may then be cultured on the matrix to form transplantable or implantable devices, including dental abutment pieces, needles, metal pins or rods, indwelling catheters, colostomy tubes, surgical meshes and any other appliance for which coating with isolated laminin-421 is desirable. Alternatively, the devices may be implanted and cells may be permitted to attach in vivo.

(54) Coupling of the isolated laminin-421 may be non-covalent (such as by adsorption), or by covalent means. The device may be immersed in, incubated in, or sprayed with the isolated laminin-421 or pharmaceutical compositions thereof.

(55) The dosage regimen for various treatments using the isolated laminin-421 of the present disclosure is based on a variety of factors, including the type of injury or condition, the age, weight, sex, medical condition of the individual, the severity of the condition, and the route of administration. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods. Laminins are extremely potent molecules, and one or a few molecules per cell could produce an effect. Thus, effective doses in the pico-gram per milliliter range are possible if the delivery is optimized.

(56) The following examples are for purposes of further illustrating the present disclosure. The examples are merely illustrative and are not intended to limit devices made in accordance with the disclosure to the materials, conditions, or process parameters set forth therein.

EXAMPLES

Cloning of the Human Laminin 2 cDNA

(57) The 5.6 kb fragment of human laminin 2 cDNA was PCR-amplified from human liver cDNA library (BD Biosciences) using primers 5-GTGGTACCCACAGGCAGAGTTGAC-3 (SEQ ID NO: 7) and 5-GCTCTAGAGCTCTTCAGTGCATAGGC-3 (SEQ ID NO: 8) thus introducing artificial XbaI and KpnI cutting sites on the ends of the fragment. To decrease the error rate during the PCR amplification Phusion high-fidelity PCR Kit (Finnzymes) was used. Subsequently, the fragment was digested with XbaI and KpnI and subcloned into pSK vector digested with the same restriction endonucleases (pSKHLAMB2 plasmid). To verify the integrity of the sequence several clones of pSKHLAMB2 plasmid were sequenced. Sequencing was performed on an ABI PRISM 310 Genetic Analyzer (Perkin Elmer) using ABI PRISM BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems). Only complete matches with the NCBI database human laminin 2 sequence were selected for further cloning.

(58) Expression Constructs

(59) For expression of the human laminin 2 chain pSKHLAMB2 plasmid was digested with XbaI and KpnI and subcloned into XbaI-KpnI treated pcDNA 3.1(+) vector (Invitrogen).

(60) The constructs used for expression of human laminin 4 (HA4 construct) and 1 (HG1 construct) have been described previously (Kortesmaa, J. et al., J. Biol. Chem. 275(20), 14853-9 (2000)).

(61) Antibodies

(62) Anti-laminin 2 (MAB2066) monoclonal antibody (mAb) was purchased from R@D Systems. Anti-laminin 4 mAb was kindly provided by Dr. Patarroyo (Wondimu, Z. Blood 104(6), 1859-66 (2004)). Anti-laminin 1 mAb (MAB1921) was purchased from CHEMICON. Anti-laminin 1 (H-190) rabbit polyclonal antibody was purchased from SANTA CRUZ Biotechnology, Inc.

(63) Production and Purification of Recombinant Laminin-421

(64) r-laminin-421 was produced in human embryonic kidney cells (HEK293, ATCC CRL-1573) cultured in DMEM, pyruvate, 10% FCS in humidified 5% CO.sub.2 atmosphere at 37 C. Wild-type cells were transfected using the standard calcium-phosphate method with the HG1 construct and stable colonies were selected using 100 mg/ml hygromycin (Cayla). All further cell culture and clonal expansion was carried out in continuous presence of relevant selection antibiotics. A highly expressing clone was then transfected with the human laminin 2 construct and stable clones were selected using 500 mg/ml G418 (LIFE TECHNOLOGIES). A clone highly expressing both laminin 1 and laminin 2 was finally transfected with the HA4 construct and stable colonies were selected using 200 mg/ml zeocin (Cayla). The clones showing the highest secretion were expanded further.

(65) For production of r-laminin-421, confluent cells were cultured in DMEM supplemented with 1 mM pyruvate and insulin-transferrin-selen supplement (SIGMA) for up to five days. r-laminin-421 was affinity purified using anti-FLAG M2 matrix (SIGMA). The collected medium was incubated in batch mode with the matrix overnight at 4 C. with agitation. Bound r-laminin-421 was competitively eluted with 50 mg/ml FLAG peptide (SIGMA) in TBS/E (50 mM Tris-CI, pH 7.5, 150 mM NaCl, 1 mM EDTA) at room temperature. The elute was concentrated and the buffer was replaced by PBS using 30 kD cut-off ultrafiltration (MILLIPORE). Finally the concentrated solution was passed through 0.2 mm filter to remove self-aggregated polymers.

(66) Characterization of Recombinant Laminin-421

(67) Secreted laminin in medium and after purification was characterized using 3-8% gradient SDS-PAGE. Proteins were visualized using Sypro staining (BIORAD) or transferred onto PVDF. The membranes were probed with antibodies described above. After washing, the membranes were incubated with HRP-conjugated goat antibodies. The immunoreactivity was detected by a chemiluminescent kit (Life Science Products) according to the manufacturer's instructions.

RESULTS

(68) Production and Characterization of Recombinant Laminin-421

(69) Conditioned medium from wild-type HEK293 cells did not react in western blotting with the anti-laminin 4, anti-laminin 2, anti-laminin 1, or anti-FLAG Abs, indicating that these cells express endogenous laminins at very low amounts if at all. After triple transfection, the best cell clone produced 2-3 mg of r-laminin-421 per liter of medium, which is quite high considering the size and complexity of the protein.

(70) Immunoaffinity purification with anti-FLAG M2 matrix followed by competitive elution with FLAG-peptide resulted in highly purified protein as seen in silver stained SDS-PAGE gels. Human r-laminin-421 was characterized using SDS-PAGE. An immunoblot of conditioned medium and r-laminin-421 was performed under non reducing and reducing conditions: Proteins on 3-8% gels were transferred onto PVDF membranes followed by staining with antibodies against laminin 4, 2 (MAB2066), 1 (MAB1921) and 1 (H-19). The control was a medium conditioned by untransfected HEK293 cells stained with antibody against laminin 4. Under reducing conditions, two bands were seen, a 220 kD band corresponding to the laminin 4 chain and a 200 kD band corresponding to the laminin 2 and 1 chains, which have similar molecular weights. In Western blotting of the conditioned medium under reducing conditions, a band of approximately 220 kDa could be seen with the laminin 4 mAb. Under non-reducing conditions, most of the protein appeared at the top of the gel as a very high molecular weight band, which was immunoreactive with 4, 2 and 1 antibodies but not 1, showing that the r-laminin-421 was produced as disulfide-crosslinked heterotrimer.

(71) The present disclosure has been described with reference to exemplary embodiments. Obviously, modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.